Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL040 in healthy volunteers
NCT05937581Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CSL040 in Complement-mediated disorder (11 arms), sponsored by CSL Limited. Primary endpoints: Treatment Emergent Adverse Events at 174 days, Adverse Events of Special Interest at 174 days and 6 more. Started Sep 2023; status: completed.
02
Drugs
CSL040
03
Conditions
Complement-mediated disorder
Beyond the preview
Go deeper on NCT05937581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937581.